Immune Regulation is a US and UK based clinical‑stage biotechnology company pioneering technologies to regulate and reset the immune system. It is developing first‑in‑class immune‑resetting therapies, including IRL201805 and IRL201104, which have shown unique efficacy and safety in pre‑clinical and human studies. These therapies have short pharmacokinetic activity but are designed to shift the immune system from a pro‑inflammatory to a regulatory state to induce long‑term disease remission without broadly suppressing immunity. The company intends to use the new funds to accelerate development of drug product candidates for autoimmune and allergic diseases. The business is led by Group CEO Jonathan Rigby and is advancing multiple programs toward clinical objectives. Financially, the company completed a Series B equity financing and raised additional advance subscription funds as described in the financing announcement.

Total raised

$52M

Funding rounds

1

Latest round

Series B

Latest activity

Sep 2020